Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.

Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur DS, Nilsson R, Sandberg B, Press OW.

Cancer Biother Radiopharm. 2008 Apr;23(2):181-91. doi: 10.1089/cbr.2007.0433.

PMID:
18454687
2.

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.

Lindén O, Kurkus J, Garkavij M, Cavallin-Ståhl E, Ljungberg M, Nilsson R, Ohlsson T, Sandberg B, Strand SE, Tennvall J.

Cancer Biother Radiopharm. 2005 Aug;20(4):457-66.

PMID:
16114994
3.

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS; Snehlata., Malhotra A.

Indian J Med Res. 2014 Apr;139(4):544-54.

4.

Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.

Wang Z, Garkavij M, Ohlsson T, Strand SE, Sjögren HO, Tennvall J.

Cancer Biother Radiopharm. 2003 Jun;18(3):365-75.

PMID:
12954123
5.

Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.

Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):787-94.

6.

Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

J Nucl Med. 2007 Feb;48(2):269-76.

7.

High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1043-52. doi: 10.1002/cncr.24791.

8.

Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5572s-5576s.

9.
10.
11.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
12.

Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH.

Anticancer Res. 2013 Jan;33(1):85-95.

PMID:
23267131
13.
14.

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.

Wang Z, Garkavij M, Tennvall JG, Ohlsson T, Strand SE, Sjögren HO.

Cancer. 2002 Feb 15;94(4 Suppl):1287-92.

15.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.

Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.

Eur J Nucl Med. 2000 Jul;27(7):766-77.

PMID:
10952488
16.

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Bäck TA, Fisher DR, Press OW.

PLoS One. 2015 Mar 18;10(3):e0120561. doi: 10.1371/journal.pone.0120561.

17.
18.

Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Yadav MP, Singla S, Thakral P, Ballal S, Bal C.

Nucl Med Commun. 2016 Jul;37(7):735-42. doi: 10.1097/MNM.0000000000000501.

PMID:
26974315
19.

Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.

Matthews DC, Badger CC, Fisher DR, Hui TE, Nourigat C, Appelbaum FR, Martin PJ, Bernstein ID.

Cancer Res. 1992 Mar 1;52(5):1228-34.

20.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

Weiden PL, Breitz HB.

Crit Rev Oncol Hematol. 2001 Oct;40(1):37-51.

PMID:
11578915
Items per page

Supplemental Content

Support Center